B2M and colorectal carcinoma: In a study conducted by Professor Peirong Ding’s team, involving 35 MSI-H CRC patients receiving PD-1 therapy, no statistically significant difference was observed in the efficacy between patients with B2M mutation and those with wild-type B2M (p=0.53).